Tag: Myokardia

MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, presented preclinical data at the American Heart Association (AHA) Scientific Sessions 2018 that demonstrated that targeting the heart’s motor protein, myosin, improved ventricular […]

MyoKardia Reports Third Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018. “MyoKardia continues to make encouraging progress toward our mission of changing the […]

MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November […]

MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be presented at the upcoming American Heart Association (AHA) Scientific Sessions […]

MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc., (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, announced a comprehensive update on its clinical-stage and emerging pipeline today at its 2018 R&D Day in New York City.  Among the highlights: […]

MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical trial. The MAVA-LTE study will assess long-term safety of […]

MyoKardia to Host R&D Day on October 30, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R&D) Day for analysts and investors on Tuesday, October 30, 2018 beginning at […]

MyoKardia to Present at the 2018 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 10:05 a.m. […]

MyoKardia to Present at Two Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming investor conferences: 2018 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, […]

New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) — The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with hypertrophic cardiomyopathy (HCM), the largest comprehensive HCM cohort assembled to […]